tirzepatide surpass-4 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Tirzepatide versus insulin glargine as – New Dual Incretin Agonist for

Yet most primary care physicians (PCPs) are skeptical of telehealth platforms prescribing GLP-1s for weight loss

This connection between weight loss and respiratory improvement has generated interest in pharmacological weight loss interventions, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, as potential adjunctive options for OSA management

Not everyone responds equally to these treatments

He will also monitor for adverse effects during treatment to ensure its safe and effective for long-term use

Endurance athletes and lifters (They're good for anyone wishing to be a tyrant.) Low-dietary intake in vegans or vegetarians

(2019) 6:e000993